Tandem and Abbott Partner on Glucose-Ketone Insulin Delivery System

Tandem Diabetes Care and Abbott are partnering to develop automated insulin delivery systems integrated with Abbott’s upcoming dual glucose-ketone sensor. This would be the first system to combine ketone sensing with insulin pumps, allowing real-time insulin adjustments and early detection of diabetic ketoacidosis.

Tandem plans to integrate the sensor into its existing insulin pumps once it gains regulatory approval. Abbott first announced plans for the sensor in 2022, highlighting its potential to prevent dangerous ketone buildup when insulin is insufficient.

While the companies haven’t disclosed timelines, Tandem is also working on its compact, tubeless Mobi pump and a patch-pump. Abbott continues expanding partnerships, including recent deals with Sequel MedTech for its Twiist AID system and Medtronic for a CGM tailored to its insulin delivery devices.

18-06-2025